UroGen Pharma Ltd. — Director's Dealing 2019

Jan 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-01

Reporting Person: Holden Stuart (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$17.67	2027-08-10	Ordinary Shares (10000)		Direct
Stock Option (right to buy)	$59.23	2028-06-04	Ordinary Shares (10000)		Direct

Footnotes

F1: 25% of the shares underlying the stock option vested on each of October 1, 2017, January 1, 2018, April 1, 2018 and July 1, 2018.

F2: 25% of the shares underlying the stock option vested on each of September 4, 2018 and December 4, 2018 and the remaining shares will in two equal installments on March 4, 2019 and June 4, 2019.